Iroxanadine
Code | Size | Price |
---|
TAR-T27627-1mg | 1mg | £188.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27627-5mg | 5mg | £352.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27627-10mg | 10mg | £496.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27627-25mg | 25mg | £760.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27627-50mg | 50mg | £1,018.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27627-100mg | 100mg | £1,348.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27627-500mg | 500mg | £2,633.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Iroxanadine, a MAPK p38 inhibitor, is used potentially for the treatment of atherosclerosis.
CAS:
276690-58-5
Formula:
C14H20N4O
Molecular Weight:
260.341
Pathway:
MAPK
Purity:
0.98
SMILES:
C(C1CONC(=N1)c1cccnc1)N1CCCCC1
Target:
p38 MAPK
References
1. Denes L, Bori Z, Csonka E, Entz L, Nagy Z. Reverse regulation of endothelial cells and myointimal hyperplasia on cell proliferation by a heatshock protein-coinducer after hypoxia. Stroke. 2008 Mar;39(3):1022-4. doi: 10.1161/STROKEAHA.107.495754. PubMed PMID: 18239173.
2. Kabakov AE, Budagova KR, Malyutina YV, Latchman DS, Csermely P. Pharmacological attenuation of apoptosis in reoxygenated endothelial cells. Cell Mol Life Sci. 2004 Dec;61(24):3076-86. PubMed PMID: 15583868.
3. Denes L, Entz L, Jancsik V. Restenosis and therapy. Int J Vasc Med. 2012;2012:406236. doi: 10.1155/2012/406236. PubMed PMID: 22489270; PubMed Central PMCID: PMC3303576.
4. D?nes L, Jedn?kovits A, Hargitai J, P?nzes Z, Balla A, T?losi L, Krajcsi P, Csermely P. Pharmacologically activated migration of aortic endothelial cells is mediated through p38 SAPK. Br J Pharmacol. 2002 Jun;136(4):597-603. PubMed PMID: 12055138; PubMed Central PMCID: PMC1573374.